Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Revenue (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Revenue for 8 consecutive years, with $34.4 million as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 55.5% year-over-year to $34.4 million; the TTM value through Mar 2026 reached $51.5 million, down 12.58%, while the annual FY2025 figure was $39.2 million, 16.7% down from the prior year.
  • Revenue hit $34.4 million in Q1 2026 for Kymera Therapeutics, up from $2.9 million in the prior quarter.
  • Across five years, Revenue topped out at $47.9 million in Q4 2023 and bottomed at $2.8 million in Q3 2025.
  • Average Revenue over 5 years is $14.5 million, with a median of $10.3 million recorded in 2024.
  • Year-over-year, Revenue surged 196.7% in 2023 and then crashed 84.56% in 2024.
  • Kymera Therapeutics' Revenue stood at $16.1 million in 2022, then surged by 196.7% to $47.9 million in 2023, then plummeted by 84.56% to $7.4 million in 2024, then plummeted by 61.18% to $2.9 million in 2025, then surged by 1097.39% to $34.4 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $34.4 million, $2.9 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.